Company profilePharmaceutical#133 of 1,318 in Pakistan✓ No DRAP alerts

MAPLE PHARMACEUTICALS (PVT) LTD

Pharmaceutical company · 127 brands · 124 molecules

Ranked #26 of 70 companies in Cardiac Care

127 registered products 51 pharmaceutical brands 124 distinct molecules 0 DRAP alerts

Company overview

127
registered products
51
pharmaceutical brands
124
distinct molecules
9
therapeutic classes
0
DRAP alerts

MAPLE PHARMACEUTICALS (PVT) LTD is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 127 product registrations across 124 distinct molecules. It is the 133rd largest registrant in Pakistan by product count, and ranks 26th of 70 in Cardiac Care. Its portfolio is concentrated in Cardiac Care and Cardiac Therapy. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by MAPLE

65 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antivirals For Systemic Use 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

57
ceilings with an approval date
1
not revised in 2+ years
2024
oldest approval year
20241
202556
Longest without revision

Top molecules by brand count

Therapeutic classes

Cardiac Care · 5Cardiac Therapy · 4Lipid Modifying Agents · 3Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 2Angiotensin-Ii Antagonists, Combinations · 1Quinolone Antibacterials · 1Anti-Infectives · 1Calcium Channel Blockers · 1Other Calcium Supplements · 1

Conditions treated

Hypertension · 3Angina · 2General Infections · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official109 products · Rs 42.9 – Rs 23,611.2
DVAGO6 products · Rs 19 – Rs 1,450
Servaid11 products · Rs 114 – Rs 549
Median across source: Rs 300.92

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

NABIQASIM INDUSTRIES (PVT) LTD. holds 172 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAcyclovir
GETZ PHARMA PAKISTAN (PVT) LTD. holds 244 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
SCOTMANN PHARMACEUTICALS holds 74 molecules not in this portfolio
AmilorideAminophyllineAmlodipineAmmonium ChlorideAmoxicillin BaseAnastrazole

Get the full profile for MAPLE

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.